Correlation of ACRBP expression in serum and tumor tissues with first-line chemotherapy and prognosis in patients with epithelial ovarian cancer
10.3969/j.issn.1673-4130.2024.10.001
- VernacularTitle:上皮性卵巢癌症患者血清和肿瘤组织中ACRBP表达与一线化疗效果和预后的关系
- Author:
Jianhong ZHAO
1
;
Hongbing CEN
;
Zhiyong YANG
Author Information
1. 长江大学附属黄冈市中心医院病理科,湖北黄冈 438000
- Keywords:
epithelial ovarian cancer;
acrosin binding protein;
first-line chemotherapy effect;
progno-sis
- From:
International Journal of Laboratory Medicine
2024;45(10):1153-1158
- CountryChina
- Language:Chinese
-
Abstract:
Objective To detect the expression of acrosin binding protein(ACRBP)in serum and tumor tissue of patients with epithelial ovarian cancer(EOC),and to investigate the relationship between the expres-sion of acrosin binding protein(ACRBP)in serum and tumor tissue of patients with epithelial ovarian cancer(EOC)and first-line chemotherapy effect and prognosis.Methods The expression and prognostic effects of ACRBP mRNA in OC were analyzed using data obtained from Gene Expression Profiling Interactive Analysis Database.Then,tissue specimens and serum samples were collected from 95 patients with EOC who under-went surgery at the hospital between October 2019 and December 2021.In addition,30 samples of ovarian be-nign tumor tissue were selected as the benign tumor control group and 30 serum samples from healthy volun-teers were selected as the normal control group.The expression of ACRBP was detected by immunohisto-chemical staining.After first-line chemotherapy was completed,solid tumor efficacy evaluation criteria version 1.1 was used to evaluate chemotherapy effects,and the patients were divided into sensitive group and drug-re-sistant group.The sensitive group included complete response(CR)and partial response(PR)patients,and the drug-resistant group included stable disease(SD)and progressive disease(PD)patients.Results In the public database,ACRBP mRNA expression was significantly increased in OC patients(P＜0.05),and its high expression was associated with poor overall survival(OS).In clinical samples,ACRBP was mainly expressed in the cytoplasm of EOC tumor cells,while no ACRBP was detected in the ovarian tissues of benign tumor control group.The expression of ACRBP in first-line chemotherapy resistant group was significantly higher than that in sensitive group,and the difference was statistically significant(P＜0.001).The area under receiv-er operating characteristic(ROC)curve of ACRBP expression for predicting first-line chemotherapy resistance was 0.830(95％CI:0.743-0.916),the cut off value was 8.65 points,and the sensitivity and the specificity were 80.0％and 77.1％,respectively.High expression of ACRBP was an independent risk factor for the prog-nosis of OS and PFS in patients with EOC(P＜0.05).According to the median expression of ACRBP,pa-tients with EOC were divided into low ACRBP expression group(＜8.27 points)and high ACRBP expression group(≥8.27 points).The OS and progression-free survival(PFS)of patients with high expression of ACRBP were significantly shorter(P＜0.05).Conclusion High expression of ACRBP in EOC patients is closely related to first-line chemotherapy resistance and poor prognosis.ACRBP has the potential to be a new biomarker for the prediction of first-line chemotherapy effect and prognosis.
